Drugs, Dollars, and Desperation

When Professor Michael Barry warns against rushing new, costly drugs into early access, he’s sparking a national debate. His argument? Many pricey treatments don’t significantly extend life and strain the national drug budget. But for families like Craig Coady’s—whose sons died from a rare disease and now fight for a life-saving drug—his words feel cold and dismissive. Patient advocates are outraged, calling his stance heartless, while politicians question whether his public comments align with government goals. The Department of Health insists Barry’s view is independent, not official policy. At the heart of the controversy: how to balance soaring drug costs with the desperate, human need for hope. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3f93294ee785dce2